当前位置: X-MOL 学术RSC Med. Chem. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Hit-to-lead optimization of a benzene sulfonamide series for potential antileishmanial agents
RSC Medicinal Chemistry ( IF 4.1 ) Pub Date : 2020-08-25 , DOI: 10.1039/d0md00165a
Paul J Koovits 1 , Marco A Dessoy 1 , An Matheeussen 2 , Louis Maes 2 , Guy Caljon 2 , Leonardo L G Ferreira 3 , Rafael C Chelucci 3 , Simone Michelan-Duarte 3 , Adriano D Andricopulo 3 , Simon Campbell 4 , Jadel M Kratz 4 , Charles E Mowbray 4 , Luiz C Dias 1
Affiliation  

A series of benzene sulphonamides with good potency and selectivity against Leishmania spp. intracellular amastigotes was identified by high-throughput screening. Approximately 200 compounds were synthesized as part of a hit-to-lead optimization program. The potency of the series appears to be strongly dependent on lipophilicity, making the identification of suitable orally available candidates challenging due to poor pharmacokinetics. Despite not identifying a clinical candidate, a likely solvent exposed area was found, best exemplified in compound 29. Ongoing detailed mode-of-action studies may provide an opportunity to use target-based medicinal chemistry to overcome the issues with the current series.

中文翻译:

潜在抗利什曼病药物苯磺酰胺系列的命中先导优化

一系列苯磺酰胺对利什曼原虫具有良好的效力和选择性。通过高通量筛选鉴定细胞内无鞭毛体。作为从命中到先导优化计划的一部分,合成了大约 200 种化合物。该系列的效力似乎强烈依赖于亲脂性,由于药代动力学较差,因此确定合适的口服候选药物具有挑战性。尽管没有确定临床候选者,但发现了可能的溶剂暴露区域,最好的例子是化合物29。正在进行的详细作用模式研究可能提供使用基于靶标的药物化学来克服当前系列的问题的机会。
更新日期:2020-11-03
down
wechat
bug